 |
 |

Molecular Imaging With Pittsburgh Compound B Confirmed at AutopsyA Case Report
Brian J. Bacskai, PhD;
Matthew P. Frosch, MD, PhD;
Stefanie H. Freeman, MD;
Scott B. Raymond, BS;
Jean C. Augustinack, PhD;
Keith A. Johnson, MD;
Michael C. Irizarry, MD;
William E. Klunk, MD, PhD;
Chester A. Mathis, PhD;
Steven T. DeKosky, MD;
Steven M. Greenberg, MD, PhD;
Bradley T. Hyman, MD, PhD;
John H. Growdon, MD
Arch Neurol. 2007;64(3):431-434.
Objective To determine the correspondence between uptake of Pittsburgh Compound B (PiB) in life and measures of β-amyloid (Aβ) in postmortem tissue analysis.
Patient A 76-year-old man with a clinical diagnosis of dementia with Lewy bodies underwent fluorodeoxyglucose 18F and PiB positron emission tomographic brain scans. Imaging revealed marked region specific binding of PiB and abnormal fluorodeoxyglucose uptake.
Intervention Autopsy was performed 3 months after the PiB scan.
Results Autopsy confirmed the clinical diagnosis; in addition, there was severe cerebral amyloid angiopathy and only moderate numbers of parenchymal Aβ plaques. Biochemical measures revealed a positive correlation between Aβ levels and regional PiB binding.
Conclusion This report confirms that PiB detects Aβ in the living patient and demonstrates that amyloid deposited as cerebral amyloid angiopathy can be the dominant source of signal.
Author Affiliations: MassGeneral Institute for Neurodegenerative Diseases, Department of Neurology, Charlestown, Mass (Drs Bacskai, Frosch, Irizarry, Greenberg, Hyman, and Growdon and Mr Raymond); C. S. Kubik Laboratory for Neuropathology (Drs Frosch and Freeman) and Department of Radiology (Drs Augustinack and Johnson), Massachusetts General Hospital, Boston; and Departments of Psychiatry (Drs Klunk and Mathis) and Neurology (Dr DeKosky), University of Pittsburgh, Pittsburgh, Pa. Dr Irizarry is now with GlaxoSmithKline, Research Triangle Park, NC.
RELATED ARTICLE
Pittsburgh Compound B Retention and Verification of Amyloid Deposition
Arch Neurol. ;64():315-316.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
 |
Assessment of {beta}-Amyloid in a Frontal Cortical Brain Biopsy Specimen and by Positron Emission Tomography With Carbon 11-Labeled Pittsburgh Compound B
Leinonen et al.
Arch Neurol 2008;0:65.10.noc80013-6.
ABSTRACT
| FULL TEXT
PET amyloid ligand [11C]PIB uptake shows predominantly striatal increase in variant Alzheimer's disease
Koivunen et al.
Brain 2008;131:1845-1853.
ABSTRACT
| FULL TEXT
Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease
Ikonomovic et al.
Brain 2008;131:1630-1645.
ABSTRACT
| FULL TEXT
Carbon 11-Labeled Pittsburgh Compound B Positron Emission Tomographic Amyloid Imaging in Patients With APP Locus Duplication
Remes et al.
Arch Neurol 2008;65:540-544.
ABSTRACT
| FULL TEXT
11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment
Jack et al.
Brain 2008;131:665-680.
ABSTRACT
| FULL TEXT
PIB is a non-specific imaging marker of amyloid-beta (A{beta}) peptide-related cerebral amyloidosis
Lockhart et al.
Brain 2007;130:2607-2615.
ABSTRACT
| FULL TEXT
A{beta} amyloid deposition in the language system and how the brain responds
Nelissen et al.
Brain 2007;130:2055-2069.
ABSTRACT
| FULL TEXT
Pittsburgh Compound B Retention and Verification of Amyloid Deposition
Holtzman
Arch Neurol 2007;64:315-316.
FULL TEXT
|